Pfizer can look forward to a faster approval process for its vaccine against respiratory syncytial virus (RSV), as the US Food and Drug Administration (FDA) will fast-track its drug review, Bloomberg reports.
The FDA’s special status, known as the Breakthrough Therapy Designation, is meant to expedite the development and case processing of drugs that treat serious diseases. RSV is a common virus that usually only leads to flu-like symptoms but can cause serious lung infections. Some at risk individuals include the elderly, immunocompromised persons and infants.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Biomarker Operations Lead 
Senior QA Specialist 
Laboratory technician for process development and clinical manufacturing 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Clinical Project Manager 
Client Talent Acquisition Specialist 
2 Sales Representatives and Product Specialists 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
(Senior) Drug Substance Specialist 
Senior Manager, Clinical Trial Budget 
Director Global Engineering 
Production Director 
Key Account Manager, Europe and Asia 
Nordic Medical Affairs Manager 
Director for innovative pre-clinical testing unit